IFNG and tuberculosis: In the present trial we have shown that DAR-901 has an acceptable safety profile, is well-tolerated in a spectrum of BCG-primed adults representing groups who will be candidates for boosting in tuberculosis-endemic countries and induces significant IFN-γ and antibody responses to polyantigenic mycobacterial antigens.